Back to search

Netherlands· NL-2b188cfbb35a

Minims Pilocarpinenitraat 20 mg/ml, oogdruppels, oplossing

A pilocarpine product containing pilocarpine nitraat, registered in Netherlands by Bausch + Lomb Ireland Limited. The same ATC class is registered in 10 of our 19 countries.

ATC S01EB01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMinims Pilocarpinenitraat 20 mg/ml, o…ATCS01EB01REGISTER NO.NL-2b188cfbb35aPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Pilocarpine is registered in 10 of 19 countries.

Countries holding a registration under ATC S01EB01 (pilocarpine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Pilocarpine · ATC S01EB01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PILOCARPINE NITRAAT
Manufacturer
Bausch + Lomb Ireland Limited
Country
Netherlands (NL)
ATC code
S01EB01
ATC class
Pilocarpine
Defined daily dose
0.285 Lamelle
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    09368

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

50 interactions on record for pilocarpine.

Graded by severity as the source publishes them — 50 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pilocarpine · interactions on record

50 records

  • 50 moderate

Most severe, free to view

  • DicycloverineA03AA07moderate
  • PropanthelineA03AB05moderate
  • MepenzolateA03AB12moderate
  • TrospiumA03AB20moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/604127b2-dd4d-4f90-bc90-66c67b0f99b9
GET /v1/drugs/604127b2-dd4d-4f90-bc90-66c67b0f99b9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oogdruppels, oplossing",
  "route": "Oculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h09368_smpc.pdf",
  "strength": null,
  "atc_label": "Pilocarpine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg09368",
  "excipients": [
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "PILOCARPINE NITRAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h09368.pdf",
  "authorised_at": "1982/01/19",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "09368",
  "additional_monitoring": "N"
}

See everything about pilocarpine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.